ARFGEF3

Across TCGA pan-cancer cohorts, ARFGEF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARFGEF3 data layer compared with 22 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARFGEF3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARFGEF3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where ARFGEF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.667	0.969	<.001	60	view →
PDAC	OS	Median	III,IV	0.494	0.222	.016	8	view →
UCEC	DFS	Median	II,III,IV	0.872	0.543	.038	4	view →
LUAD	DFS	Median	II,III,IV	0.775	0.931	.018	4	view →
GBM	DFS	Quartile	All	0.855	0.622	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARFGEF3–CCRCC (OS)

Open the CCRCC breakdown →